4.8 Review

Chronic obstructive pulmonary disease

期刊

LANCET
卷 389, 期 10082, 页码 1931-1940

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(17)31222-9

关键词

-

资金

  1. AstraZeneca
  2. Takeda
  3. Chiesi
  4. Novartis
  5. Boehringer Ingelheim
  6. Sanofi Aventis
  7. Berlin Chemie
  8. Teva
  9. GlaxoSmithKline
  10. AstraZeneca
  11. Takeda
  12. Chiesi
  13. Novartis
  14. Boehringer Ingelheim
  15. Sanofi Aventis
  16. Berlin Chemie
  17. Teva
  18. GlaxoSmithKline

向作者/读者索取更多资源

Chronic obstructive pulmonary disease (COPD) kills more than 3 million people worldwide every year. Despite progress in the treatment of symptoms and prevention of acute exacerbations, few advances have been made to ameliorate disease progression or affect mortality. A better understanding of the complex disease mechanisms resulting in COPD is needed. Smoking cessation programmes, increasing physical activity, and early detection and treatment of comorbidities are further key components to reduce the burden of the disease. However, without a global political and economic effort to reduce tobacco use, to regulate environmental exposure, and to find alternatives to the massive use of biomass fuel, COPD will remain a major health-care problem for decades to come.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据